Key Highlights
- Fourth-quarter sales reached $9.81 billion, surpassing the Street’s $9.63 billion projection.
- Adjusted earnings per share of $1.55 exceeded the consensus forecast of $1.54.
- Cardiovascular division revenue surged 13.8% to $3.8 billion, with Cardiac Ablation Solutions skyrocketing 78% worldwide.
- Fiscal 2027 adjusted EPS outlook of $5.90–$6.00 trails analyst expectations of $6.06; tariff-related costs projected at approximately $300 million.
- Quarterly dividend increased for the 49th consecutive year to $0.72 per share ($2.88 on an annual basis).
Medtronic delivered its most impressive full-year sales expansion in ten years, powered by robust demand across its cardiac device portfolio. Fourth-quarter sales of $9.81 billion exceeded Wall Street’s $9.63 billion projection, while adjusted earnings per share of $1.55 narrowly topped the $1.54 Street consensus. The medical technology giant’s full-year organic revenue expansion of 5.8% represents its strongest annual showing in a decade.
While topline results impressed, certain areas showed weakness — particularly the fiscal 2027 EPS guidance of $5.90 to $6.00, which missed the $6.06 analyst forecast.
Trade tariff expenses represent a tangible headwind. Management anticipates approximately $300 million in fiscal 2027 impact, escalating from roughly $185 million in fiscal 2026. Leadership has been transparent about these mounting pressures.
Cardiac Portfolio Powers Performance
The cardiovascular division clearly led the charge this quarter. Sales climbed 13.8% to $3.8 billion — representing nearly 40% of consolidated revenue. Cardiac Ablation Solutions exploded 78% globally, including spectacular 124% U.S. expansion, capturing an additional 8 market share points.
Pulsed field ablation technology and transcatheter aortic valve replacement procedures are experiencing the steepest adoption trajectories currently, with Medtronic establishing significant traction in both categories.
The Micra leadless pacemaker delivered mid-teens percentage growth, while the OmniaSecure defibrillation lead enjoyed a successful domestic market introduction.
Neuroscience division revenue advanced 5% to $2.75 billion, slightly trailing the $2.76 billion analyst projection. The Medical Surgical segment generated $2.39 billion, climbing 8% on a reported basis and 5.1% organically, with Acute Care & Monitoring achieving low double-digit expansion.
Diabetes revenue increased 15% on a reported basis to $837 million, with the division remaining under Medtronic ownership throughout the complete 12-month FY27 guidance period.
Acquisitions and Development Pipeline
Medtronic has maintained an aggressive tuck-in acquisition strategy following its diabetes unit spinoff. Throughout the quarter and fiscal year, the company finalized the CathWorks transaction, revealed intentions to acquire Scientia Vascular and SPR Therapeutics (for approximately $650 million), and submitted FDA clearance applications for its Hugo robotic-assisted surgery platform covering general surgery and gynecologic procedures.
The Hugo regulatory submission marks a significant milestone for its surgical robotics strategy — a competitive arena where Medtronic has been methodically advancing its position.
The corporation also elevated its quarterly dividend payment to $0.72 per share, extending its dividend growth streak to 49 consecutive years.
For fiscal 2027, Medtronic projects organic revenue growth between 6.75% and 7.25%. Full-year fiscal 2026 revenue totaled $36.4 billion on an 8.4% reported basis and 5.8% organic expansion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
